Go Pro
→ I went to a party with Elon... (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
C$0.79
C$0.79
C$0.40
▼
C$0.79
C$14.71M-1.54871842,290 shs1,164 shs
HEXO Corp. stock logo
HEXO
HEXO
C$0.00
C$0.85
▼
C$4.97
C$38.72M2.13253,024 shs72,643 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$11.09
-3.6%		$9.96
$4.82
▼
$11.94
$1.95B1.632.21 million shs1.68 million shs
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
C$0.15
-3.2%		C$0.16
C$0.07
▼
C$0.20
C$33.95M0.476281119,222 shs158,500 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
0.00%0.00%0.00%0.00%+66.32%
HEXO Corp. stock logo
HEXO
HEXO
0.00%0.00%0.00%0.00%0.00%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-3.57%+5.42%+11.91%+12.25%+114.51%
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
-3.23%-11.76%-9.09%+36.36%-3.23%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
C$0.79
C$0.79
C$0.40
▼
C$0.79
C$14.71M-1.54871842,290 shs1,164 shs
HEXO Corp. stock logo
HEXO
HEXO
C$0.00
C$0.85
▼
C$4.97
C$38.72M2.13253,024 shs72,643 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$11.09
-3.6%		$9.96
$4.82
▼
$11.94
$1.95B1.632.21 million shs1.68 million shs
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
C$0.15
-3.2%		C$0.16
C$0.07
▼
C$0.20
C$33.95M0.476281119,222 shs158,500 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
0.00%0.00%0.00%0.00%+66.32%
HEXO Corp. stock logo
HEXO
HEXO
0.00%0.00%0.00%0.00%0.00%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-3.57%+5.42%+11.91%+12.25%+114.51%
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
-3.23%-11.76%-9.09%+36.36%-3.23%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
0.00
N/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
0.00
N/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.88
Moderate Buy$21.5794.51% Upside
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CTX, HEXO, VIR, and VM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
7/8/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
C$23.22M0.63C$0.66 per share1.20C$0.77 per share1.02
HEXO Corp. stock logo
HEXO
HEXO
C$124.10M0.00N/A1.55C$3.24 per share0.00
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$302.59M6.20N/AN/A$5.50 per share2.02
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
C$47.24K718.71C$0.00 per share35.00C$0.00 per share65.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
-C$2.61M-C$0.01N/AN/AN/A-1.38%-2.07%-8.26%N/A
HEXO Corp. stock logo
HEXO
HEXO
-C$273.18M-C$3.41N/AN/A-220.13%-106.39%-14.96%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$437.99M-$1.86N/AN/AN/A-638.88%-29.99%-23.62%11/4/2026 (Estimated)
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
-C$1.66M-C$0.02N/AN/AN/A-8,033.93%-403.29%-30.77%N/A

Latest CTX, HEXO, VIR, and VM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$0.3326$0.47+$0.1374$0.47$135.88 million$238.95 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
N/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
17.34
2.80
2.29
HEXO Corp. stock logo
HEXO
HEXO
125.99
0.41
0.40
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.04
6.04
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
9.80
0.23
0.84

Institutional Ownership

CompanyInstitutional Ownership
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
3.14%
HEXO Corp. stock logo
HEXO
HEXO
7.57%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
10.87%
HEXO Corp. stock logo
HEXO
HEXO
3.03%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.90%
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
10.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescita Therapeutics Inc. stock logo
CTX
Crescita Therapeutics
6218.61 millionN/ANot Optionable
HEXO Corp. stock logo
HEXO
HEXO
69044.00 millionN/ANot Optionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
367169.22 million164.31 millionOptionable
Voyageur Pharmaceuticals Ltd. stock logo
VM
Voyageur Pharmaceuticals
N/A226.34 millionN/ANot Optionable

Recent News About These Companies

Voyageur Pharmaceuticals aims for Q2 2027 FDA approval to lead medical imaging supply chain
August 5, 2026  |  bnnbloomberg.caB
VM:CA Voyageur Pharmaceuticals Ltd.
July 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/VM:CA
Voyageur Pharmaceuticals Ltd.: Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
July 17, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69061424-voyageur-pharmaceuticals-ltd-voyageur-pharmaceuticals-announces-the-engagement-of-red-cloud-securities-as-market-maker-296.htm
Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption
June 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/voyageur-announces-closing-non-brokered-225156925.html
Voyageur Announces Non-Brokered Life Offering
March 25, 2026  |  mining.comhttps://www.mining.com/press-release?id=69c3e21456056c864313e750
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial With Alberta Innovates Grant; Announces ...
March 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/voyageur-pharmaceuticals-confirms-pharmaceutical-grade-140111512.html
Voyageur Pharmaceuticals Gains Full Control of Iodine Technology, Names New Director of Chemistry
January 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/37019696/voyageur-pharmaceuticals-gains-full-control-of-iodine-technology-names-new-director-of-chemistry/
Voyageur Pharmaceuticals Strengthens Board for U.S. Expansion
November 7, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/voyageur-pharmaceuticals-strengthens-board-for-u-s-expansion?utm_source=marketbeat.com&utm_medium=referral
Voyageur Pharmaceuticals Expands Board with Wall Street Experts for U.S. Market Growth
October 23, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/voyageur-pharmaceuticals-expands-board-with-wall-street-experts-for-u-s-market-growth?utm_source=marketbeat.com&utm_medium=referral
Voyageur Pharmaceuticals Launches First Commercial Shipments of Barium Contrast Products in Canada
August 21, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/voyageur-pharmaceuticals-launches-first-commercial-shipments-of-barium-contrast-products-in-canada/ar-AA1KXB1B
Voyageur Pharmaceuticals Gains $1.69 Million from Warrant Exercise
August 20, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/voyageur-pharmaceuticals-gains-1-69-million-from-warrant-exercise/ar-AA1KQoYn
Voyageur Pharmaceuticals Advances Frances Creek Project with VAST Engagement
August 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/voyageur-pharmaceuticals-advances-frances-creek-project-with-vast-engagement/ar-AA1KK068
Voyageur Pharmaceuticals Ltd. (CVE:VM) Director Eugene Leonard Fritzel Acquires 32,250 Shares
July 1, 2025  |  insidertrades.comhttps://www.insidertrades.com/alerts/cve-vm-insider-buying-and-selling-2025-07-01/
Voyageur Pharmaceuticals Launches First Commercial Sale of Barium Contrast Agents
June 4, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/voyageur-pharmaceuticals-launches-first-commercial-sale-of-barium-contrast-agents/ar-AA1G5IaL
Voyageur Launches Market Introduction of Barium Contrast Product Line Following Successful Clinical Study Results
April 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/voyageur-launches-market-introduction-barium-143457102.html
Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch
April 1, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/voyageur-completes-human-testing-barium-120000757.html
Voyageur Pharmaceuticals Ltd.: Voyageur Clarifies Terms of Previously Announced Agreement
March 3, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64715935-voyageur-pharmaceuticals-ltd-voyageur-clarifies-terms-of-previously-announced-agreement-296.htm
Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes
February 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/voyageur-advances-mri-drug-development-232956159.html
Voyageur Pharmaceuticals With CEO, Brent Willis | February 6th, 2025
February 6, 2025  |  msn.comhttps://www.msn.com/en-ca/money/topstories/voyageur-pharmaceuticals-with-ceo-brent-willis-february-6th-2025/vi-AA1yyeo6
Voyageur Receives $600K Grant From Alberta Innovates for Product Development
February 6, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/voyageur-receives-600k-grant-alberta-120000259.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Close-up of a carbon fiber surface bearing the AV logo and a camera sensor.
AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone Opportunity
By Ryan Hasson | September 3, 2026
Autonomous military drone with AV-style logo on the nose sitting on a runway, representing AeroVironment and the defense drone industry.
AeroVironment's Record Backlog and Earnings Beat Fuel Recovery Case
By Thomas Hughes | September 10, 2026
Laptop displaying a candlestick stock price chart on a desk with autumn leaves and the word September overlaid.
5 Stocks to Buy in September Before Wall Street Catches On
By Thomas Hughes | August 26, 2026
Conceptual pie chart with segments depicting industry sectors like agriculture, shipping, energy, robotics, and technology against a city skyline.
Venture Into High-Volatility Corners of the Market With These 3 ETFs
By Nathan Reiff | August 29, 2026
Three military surveillance drones fly near a mobile radar unit at an airfield during sunset.
3 Defense Stocks Riding the High-Energy Laser Boom
By Nathan Reiff | September 15, 2026
Crescita Therapeutics stock logo

Crescita Therapeutics TSE:CTX

C$0.79 0.00 (0.00%)
As of 06/4/2026

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.

HEXO stock logo

HEXO TSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$11.09 -0.41 (-3.57%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$11.00 -0.09 (-0.80%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Voyageur Pharmaceuticals stock logo

Voyageur Pharmaceuticals CVE:VM

C$0.15 -0.01 (-3.23%)
As of 09/23/2026 02:30 PM Eastern

Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. was founded in 2017 and is headquartered in Calgary, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas